Inhaled beta-2-agonists/muscarinic antagonists and acute myocardial infarction in COPD patients

Respiratory Medicine

Volumn 108, Issue 8, 2014, Pages 1075-1090

  Rottenkolber, Marietta ^a   Rottenkolber, Dominik ^a,b   Fischer, Rainald ^c   Ibáñez, Luisa ^d,e   Fortuny, Joan ^f   Ballarin, Elena ^d,e   Sabaté, Monica ^d,e   Ferrer, Pili ^d   Thürmann, Petra ^g,h   Hasford, Joerg ^a   Schmiedl, Sven ^g,h  

^a UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f Departamento médico   (Spain)

^g HELIOS KLINIKUM WUPPERTAL   (Germany)

^h UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Acute myocardial infarction; Beta 2 agonists; Chronic obstructive pulmonary disease; Muscarinic antagonists; Systematic review

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; TIOTROPIUM BROMIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; SCOPOLAMINE DERIVATIVE;

ACUTE HEART INFARCTION; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; DATA BASE; DISEASE CONTROL; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT INDICATION; CHEMICALLY INDUCED; EPIDEMIOLOGY; HEART INFARCTION; INHALATIONAL DRUG ADMINISTRATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; CHOLINERGIC ANTAGONISTS; EPIDEMIOLOGIC METHODS; HUMANS; MUSCARINIC ANTAGONISTS; MYOCARDIAL INFARCTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SCOPOLAMINE DERIVATIVES;

EID: 84906327699     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2014.05.014     Document Type: Review

References (48)

1. Global Initiative for Chronic Obstructive Lung disease (GOLD) Global strategy for the diagnosis, management and prevention of COPD 2014 [updated 2014; cited 18/May/2014]; Available from: http://www.goldcopd.org
2. S.R. Salpeter Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review Drugs Aging 21 2004 405 414
3. S. Singh, Y.K. Loke, P. Enright, and C.D. Furberg Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications Thorax 68 2013 114 116
4. D.H. Au, J.R. Curtis, N.R. Every, M.B. McDonell, and S.D. Fihn Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction Chest 121 2002 846 851
5. S. Suissa, T. Assimes, and P. Ernst Inhaled short acting beta agonist use in COPD and the risk of acute myocardial infarction Thorax 58 2003 43 46
6. B. Zhang, F. de Vries, E. Setakis, and T.P. van Staa The pattern of risk of myocardial infarction in patients taking asthma medication: a study with the General Practice Research Database J Hypertens 27 2009 1485 1492
7. R.G. Barr, J. Bourbeau, C.A. Camargo, and F.S. Ram Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis Thorax 61 2006 854 862
8. B. Celli, M. Decramer, I. Leimer, U. Vogel, S. Kesten, and D.P. Tashkin Cardiovascular safety of tiotropium in patients with COPD Chest 137 2010 20 30
9. D.P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten, and S. Menjoge et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med 359 2008 1543 1554
10. C. Vogelmeier, B. Hederer, T. Glaab, H. Schmidt, M.P. Rutten-van Molken, and K.M. Beeh et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD N Engl J Med 364 2011 1093 1103
11. C. de Luise, S.F. Lanes, J. Jacobsen, L. Pedersen, and H.T. Sorensen Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark Eur J Epidemiol 22 2007 267 272
12. M. Jara, C. Wentworth 3rd, and S. Lanes A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD BMJ Open 2 2012 pii: e000841
13. K.M. Verhamme, A.S. Afonso, C. van Noord, M.D. Haag, P.J. Koudstaal, and G.G. Brusselle et al. Tiotropium Handihaler and the risk of cardio- or cerebrovascular events and mortality in patients with COPD Pulm Pharmacol Ther 25 2012 19 26
14. S.M. Curkendall, C. DeLuise, J.K. Jones, S. Lanes, M.R. Stang, and E. Goehring Jr. et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients Ann Epidemiol 16 2006 63 70
15. A.K. Johnston, D.M. Mannino, G.W. Hagan, K.J. Davis, and V.A. Kiri Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort Thorax 63 2008 599 605
16. S. Kesten, M. Jara, C. Wentworth, and S. Lanes Pooled clinical trial analysis of tiotropium safety Chest 130 2006 1695 1703
17. D.D. Sin, and S.F. Man Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease Circulation 107 2003 1514 1519
18. F. de Vries, S. Pouwels, M. Bracke, J.W. Lammers, O. Klungel, and H. Leufkens et al. Use of beta2 agonists and risk of acute myocardial infarction in patients with hypertension Br J Clin Pharmacol 65 2008 580 586
19. P.M. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, C. Jenkins, and P.W. Jones et al. Cardiovascular events in patients with COPD: TORCH study results Thorax 65 2010 719 725
20. Y.H. Dong, H.H. Lin, W.Y. Shau, Y.C. Wu, C.H. Chang, and M.S. Lai Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials Thorax 68 2013 48 56
21. G.J. Rodrigo, J.A. Castro-Rodriguez, L.J. Nannini, V. Plaza Moral, and E.A. Schiavi Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis Respir Med 103 2009 1421 1429
22. J.A. Wedzicha, P.M. Calverley, T.A. Seemungal, G. Hagan, Z. Ansari, and R.A. Stockley The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide Am J Respir Crit Care Med 177 2008 19 26
23. J.S. Alpert, K. Thygesen, E. Antman, and J.P. Bassand Myocardial infarction redefined-a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction J Am Coll Cardiol 36 2000 959 969
24. A.S. Buist, M.A. McBurnie, W.M. Vollmer, S. Gillespie, P. Burney, and D.M. Mannino et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study Lancet 370 2007 741 750
25. L.S. Jonsdottir, N. Sigfusson, H. Sigvaldason, and G. Thorgeirsson Incidence and prevalence of recognised and unrecognised myocardial infarction in women. The Reykjavik Study Eur Heart J 19 1998 1011 1018
26. D.M. Mannino, and A.S. Buist Global burden of COPD: risk factors, prevalence, and future trends Lancet 370 2007 765 773
27. T.E. O'Toole, D.J. Conklin, and A. Bhatnagar Environmental risk factors for heart disease Rev Environ Health 23 2008 167 202
28. S. Yusuf, S. Hawken, S. Ounpuu, T. Dans, A. Avezum, and F. Lanas et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 2004 937 952
29. R.G. Barr, B.R. Celli, D.M. Mannino, T. Petty, S.I. Rennard, and F.C. Sciurba et al. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD Am J Med 122 2009 348 355
30. S.P. Bhatt, and M.T. Dransfield Chronic obstructive pulmonary disease and cardiovascular disease. Translational research J Lab Clin Med 162 2013 237 251
31. J.L. Lopez-Campos, and C.C. Acuna What is in the guidelines about the pharmacological treatment of chronic obstructive pulmonary disease? Expert Rev Respir Med 7 2013 43 51
32. D.P. Tashkin, and L.M. Fabbri Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents Respir Res 11 2010 149
33. P.M. Calverley, and S. Scott Is airway inflammation in chronic obstructive pulmonary disease (COPD) a risk factor for cardiovascular events? COPD 3 2006 233 242
34. L. Huiart, P. Ernst, X. Ranouil, and S. Suissa Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD Eur Respir J Off J Eur Soc Clin Respir Physiol 25 2005 634 639
35. L. Huiart, P. Ernst, X. Ranouil, and S. Suissa Oral corticosteroid use and the risk of acute myocardial infarction in chronic obstructive pulmonary disease Can Respir J 13 2006 134 138
36. C. Varas-Lorenzo, L.A. Rodriguez, A. Maguire, J. Castellsague, and S. Perez-Gutthann Use of oral corticosteroids and the risk of acute myocardial infarction Atherosclerosis 192 2007 376 383
37. D. Price, S. Bosnic-Anticevich, A. Briggs, H. Chrystyn, C. Rand, and G. Scheuch et al. Inhaler competence in asthma: common errors, barriers to use and recommended solutions Respir Med 107 2013 37 46
38. A. Garcia Arieta On comparing different devices of inhalation products Respir Med 103 2009 1774 1775 author reply 6
39. M. Ichinose, T. Fujimoto, and Y. Fukuchi Tiotropium 5microg via respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients Respir Med 104 2010 228 236
40. J.A. van Noord, P.J. Cornelissen, J.L. Aumann, J. Platz, A. Mueller, and C. Fogarty The efficacy of tiotropium administered via respimat soft mist inhaler or handihaler in COPD patients Respir Med 103 2009 22 29
41. E.D. Bateman, D. Tashkin, N. Siafakas, R. Dahl, L. Towse, and D. Massey et al. A one-year trial of tiotropium respimat plus usual therapy in COPD patients Respir Med 104 2010 1460 1472
42. S. Singh, Y.K. Loke, P.L. Enright, and C.D. Furberg Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials BMJ 342 2011 d3215
43. K.M. Verhamme, N. van Blijderveen, and M.C. Sturkenboom Tiotropium and the risk of death in COPD N Engl J Med 370 2014 481 482
44. R.A. Wise, A. Anzueto, D. Cotton, R. Dahl, T. Devins, and B. Disse et al. Tiotropium respimat inhaler and the risk of death in COPD N Engl J Med 369 2013 1491 1501
45. Y.K. Loke, S. Singh, and C.D. Furberg Tiotropium and the risk of death in COPD N Engl J Med 370 2014 480 481
46. D.P. Tashkin, and G.T. Ferguson Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease Respir Res 14 2013 49
47. J.A. van Noord, J.L. Aumann, E. Janssens, J.J. Smeets, J. Zaagsma, and A. Mueller et al. Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms Respir Med 104 2010 995 1004
48. J. Wang, D. Jin, P. Zuo, T. Wang, Y. Xu, and W. Xiong Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis Respirology 16 2011 350 358